chrisvoncsefalvay/vaers-outcomes huggingface dataset:
In the middle of the night a little more than 24 hours after receiving my pneumonia vaccine, I began to feel even stronger pains than usual. When I woke up on Saturday morning (I had received my vaccine on Thursday evening), I noticed that I had a large, red, swollen mark where my vaccine had been received. In the preceding 48 hours I had increasingly higher fevers and chills (vacillating between 94 and 101), headaches, muscle aches in my neck, shoulders, and back, and I could not move my arm above my head, or put on a shirt without excruciating pain (like a 6 or 7 on a 10-point pain scale). My resting heart rate was between 80 and 110 bpm (it's typically 60-70). The swelling grew in size at about half an inch a day (both deep and wide). I could barely lift anything or bend down either. I began immediately taking Advil and Benadryl, and applying hydrocortisone cream to the site. I also rested, drank a lot of water, and applied hot and cold packs to the site. However, each day it worsened. Finally, on Monday morning I went back to the pharmacist who immunized me - and a physicians assistant at a local clinic - and both seemed alarmed, but told me to wait and keep applying the same treatments I had been doing. The physicians assistant told me to come back on Wednesday to receive antibiotics if conditions did not improve. However, as the conditions kept worsening, on Monday evening, approximately 96 hours after receiving the vaccine, I consulted with my mother (a retired RN nurse) and she recommended I try taking azitromicina (Z-pack) as this seemed particularly severe to her. I did so, and 12 hours after my first dose - as I write this - my fever has been reduced (to about 99) and more importantly the vaccination spot has not grown in size today. I will be completing the Z-pack and updating you with results.
Severe headache, extremely tired, left upper and lower arm had a raised rash, very itchy (looked like goose bumps).
at time of jab, slight tenderness.  A few weeks later, severe pain developed thru upper body, radiating from right shoulder and back. Pain was severe, scale 10/10, and constant, with excruciating flare ups in the evening.  Low strength in right bicep -  cannot hold arm out.  - Chiropractic treatment has aleviated most of the pain,  very little  strength has returned.
Fever  -24 Hours, Chills - 24 Hours, Aches -24 Hours, Fatigue - 4 days+ (ongoing), lymph node swelling in neck and breast/underarm - 4 days+ (ongoing)
This spontaneous report as received from a healthcare worker refers to unknown number of patients of unspecified age and gender who on unknown dates received GARDASIL (doses, routes and lot numbers not reported) exposed to 11 C for 96 hours. No adverse effect reported. This is one of several reports received from the same source. Attempts are being made to distinguish individual patients mentioned in this report.
I had shortness of breath, a cough, a fever, body weakness and muscle aches. I felt like garbage.
1 - 1  1/2 days after getting the vaccine I started having a dry cough, difficulty breathing, chest pain, itching in my hands and feet, weakness, neck and shoulder pain and my mouth is extremely dry. I have 2 inhalers and a nebulizer and am now on steroids and it isn?t helping my breathing.
pt recv vax & exp bowel problems;ultrasound OK knee, depression, bone pain, vomiting, h/a, gall bladder attacks, heart & sternum pain;all new since recv vax;
Patient's arm began to swell and turn visibly red from injection site down to wrist. Patient complained of pain in arm. Patient was given an ice pack to help.
neuropathy in her right hand; Heart rate of 150; cough; hair loss; red spots on face; no appetite; GI upset; This spontaneous case was reported by a consumer and describes the occurrence of NEUROPATHY PERIPHERAL (neuropathy in her right hand) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product TUCATINIB (TUKYSA) for Neoplasm breast.    Concurrent medical conditions included Malignant neoplasm of female breast.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form and TUCATINIB (TUKYSA) (unknown route) at an unspecified dose. On an unknown date, the patient experienced NEUROPATHY PERIPHERAL (neuropathy in her right hand) (seriousness criterion medically significant), HEART RATE INCREASED (Heart rate of 150), COUGH (cough), ALOPECIA (hair loss), ERYTHEMA (red spots on face), DECREASED APPETITE (no appetite) and ABDOMINAL DISCOMFORT (GI upset). At the time of the report, NEUROPATHY PERIPHERAL (neuropathy in her right hand), HEART RATE INCREASED (Heart rate of 150), COUGH (cough), ALOPECIA (hair loss), ERYTHEMA (red spots on face), DECREASED APPETITE (no appetite) and ABDOMINAL DISCOMFORT (GI upset) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In April 2021, Blood bilirubin: elevated (High) Elevated.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medications were reported.  On 12-MAR-2021, it was reported that the patient was in the emergency room (ER). She was complaining of heart rate of 150 and cough. She states, "I got Moderna Vaccine the day before I started my Tukysa, I am not sure which one or both are doing this.  On 03-MAY-2021, it was reported that Patient reports that Tukysa was on hold for about a week from 16-APR-2021 to 22-APR-2021 because her bilirubin level was elevated. Patient reports that she also has little red spots on her face, they do not itch and are not painful. Patient states that she has no appetite and has a lot of GI upset. Patient states that she is beginning to lose her hair. Patient also states that she had some neuropathy in her R hand.  This case refers to a 63-yearold female patient receiving cancer treatment who experienced some events after the administration of the vaccine on an unspecified date. Very limited information regarding these events has been provided at this time. Further information has been requested.   Most recent FOLLOW-UP information incorporated above includes: On 03-May-2021: additional adverse events were updated, case upgraded to serious, action taken with Tukysa was updated.; Sender's Comments: This case refers to a 63-yearold female patient receiving cancer treatment who experienced some events after the administration of the vaccine on an unspecified date. Very limited information regarding these events has been provided at this time. Further information has been requested.
Information has been received from a registered nurse referring to a patient of unknown age and gender. Information about medical history and concurrent condition was not reported. On 13-FEB-2015 the patient was vaccinated with improperly stored PNEUMOVAX23 lot # K010465 with expiration date of 23-MAR-2016; dosage and route unspecified) (incorrect product storage). No adverse symptoms were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Patient presented to vaccine clinic to receive 2nd dose of Moderna and received Pfizer vaccine instead.
her blood pressure was 88 over something/her pressure was very low; started having some difficulties, then Friday was the worst, she couldn't hardly walk no appetite; started having some difficulties, then Friday was the worst, she couldn't hardly walk no appetite; weak; diarrhea; listless; This is a spontaneous report from a contactable consumer or other non hcp. An 80-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: N6203), intramuscular, administered in Arm Left on 24Feb2021 (at the age of 80-year-old) as dose 1, single for covid-19 immunisation. Medical history was reported as none. There were no concomitant medications. History of all previous immunization with the Pfizer vaccine considered as suspect was reported as none. Caller reported that he and his wife got their first Pfizer covid vaccine dose on 24Feb and his wife started having some difficulties, then Friday (unspecified date) was the worst, she could not hardly walk, she became weak, has had no appetite, they called the doctor, the doctor they said they had to get checked out for covid first. They went to get checked out and were reported negative for covid. The doctor seems to think that the vaccination caused the problem. The doctor suggested for them to call Pfizer and advise them on what to do. He wanted to know if he and his wife can go for second shot scheduled on 17Mar2021 or not. Upon follow-up patient herself explained every day after she received the shot, she got weaker and weaker. Patient clarified events began on Thursday, 25Feb2021. She got the shakes sometimes it was uncontrollable. She also had diarrhea. At one point, it got so bad she could not walk. She mentioned she had no appetite, she was listless. She could not think of all the different things that went wrong. Every day was a slight improvement. She was doing physical therapy, she clarified as of today (unspecified date), she had it. She states her doctor took a cardiogram and her blood pressure was 88 over something, her pressure was very low. She stated the doctor also took a couple of vials of blood. She does not have the results yet. The patient underwent lab tests and procedures which included echocardiogram: blood pressure was 88 on cardiogram and her blood pressure was 88 over something, her pressure was very low, sars-cov-2 test: negative on an unspecified date. Patient visited physician office for adverse events. The outcome of events was unknown.  No follow-up attempts are possible. No further information is expected.
4th dose - 12Apr2022, lot number 001M21A; He also had aching body; He has a cough and a runny nose; His breathing was a little worse than normal/it is his breathing that is concerning him; He has a cough and a runny nose; His temperature was slightly high; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (He also had aching body), COUGH (He has a cough and a runny nose), DYSPNOEA (His breathing was a little worse than normal/it is his breathing that is concerning him), RHINORRHOEA (He has a cough and a runny nose) and PYREXIA (His temperature was slightly high) in a 62-year-old male patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Question:Describe relevant medical history/conditions, allergy, concomitant diseases and risk factor.Answer:COPD.  The patient's past medical history included COPD. Previously administered products included for Drug use for unknown indication: Moderna (1st dose: lot number 025J20-2A) on 09-Jan-2021, Moderna (2nd dose -lot number 012M20A) on 11-Feb-2021, Moderna (3rd dose-Lot number 049E21A) on 04-Nov-2021, Spikevax (4th dose- Lot number 001M21A) on 12-Apr-2022, Moderna (5th dose-lot number was unknown) on 17-Nov-2022 and Flu vaccine. Past adverse reactions to the above products included No adverse reaction with Flu vaccine, Moderna, Moderna, Moderna, Moderna and Spikevax. Concomitant products included PREDNISONE for an unknown indication.    On 29-Oct-2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On 02-Nov-2023, the patient experienced PAIN (He also had aching body). 02-Nov-2023, the patient experienced COUGH (He has a cough and a runny nose), DYSPNOEA (His breathing was a little worse than normal/it is his breathing that is concerning him), RHINORRHOEA (He has a cough and a runny nose) and PYREXIA (His temperature was slightly high). On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (4th dose - 12Apr2022, lot number 001M21A). At the time of the report, PAIN (He also had aching body), COUGH (He has a cough and a runny nose), DYSPNOEA (His breathing was a little worse than normal/it is his breathing that is concerning him), RHINORRHOEA (He has a cough and a runny nose) and PYREXIA (His temperature was slightly high) was resolving and WRONG PRODUCT ADMINISTERED (4th dose - 12Apr2022, lot number 001M21A) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: Slightly high (100 degrees)..     For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter did not provide any causality assessments.   No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-748628, US-MODERNATX, INC.-MOD-2023-748631, US-MODERNATX, INC.-MOD-2023-748624 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-748628:Wife Case (Monovalent) US-MODERNATX, INC.-MOD-2023-748631:Wife Case (Bivalent)
10/20/09 Client received vaccine and states that 3 hours later she started to develop hives. Did not seek treatment or take medication until 10/21/09 when she saw MD and started BENADRYL PO. Next day hives progressed to entire body so she went to ER and was given 5 day prednisone regimen (10/22/09).
Large hard bump on day 1, day 2 it became smaller but more spread out and red. Hot and itchy from day 1. Taken benadryl both days. Slight improvement.
flulike symptoms, body aches, loss of appetite, headache lasting  2 1/2 days. The effects were less than 1st dose where I had full blown COVID symptoms.   I Had COVID in early December was ill for 14 days.
Patient is complaining her arm still hurts one month post vaccination. Does not hurt all of the time but has soreness intermittently & sporadically.
Had rash develop on both hands and were swelling. Advised member to go to ER due to all of her allergies.
Pain, redness, nodule, warmth to touch. Injection given Monday 9/24/11 at 10am. Noticed redness 9/27/11 which continued to progress from injection site down arm. Treated with Prednisone pak - 6 day course.
he was fully vaccinated, he got his 2nd dose in February; a high profile figure, died of the covid-19 virus; This is a spontaneous report from contactable consumers. An 84-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as dose 1, single and via an unspecified route of administration on Feb2021 (Batch/Lot number was not reported) as dose 2, single for covid-19 immunisation. Medical history included multiple myeloma - a type of blood cancer that can limit the body's ability to fight infection and Parkinson's disease. The patient's concomitant medications were not reported. The patient who was a high-profile figure, died of the covid-19 virus. He had received the vaccine. From what the reporter had heard, he may have been battling cancer and so was autoimmune compromised. The patient received his second dose of the Pfizer-BioNTech vaccine in February, said his longtime aide. He had been scheduled for a booster last week but before he received it, she said (as reported). The patient died Monday as a result of complications from COVID-19, his family said. He was fully vaccinated against the virus but had been treated over the past few years for multiple myeloma - a type of blood cancer that can limit the body's ability to fight infection, according to his longtime aide. The patient died on 18Oct2021 due to drug ineffective and suspected COVID-19. It was unknown if an autopsy was performed.  The lot number for BNT162B2, was not provided and will be requested during follow up; Reported Cause(s) of Death: he was fully vaccinated, he got his 2nd dose in February; (Name), a high profile figure, died of the covid-19 virus
Family Medicine Encounter for screening laboratory testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  Dx Cough ? Sore Throat ? Nasal Congestion ? Nausea  10/29/2021 COVID 19 MAB Infusion   ED to Hosp-Admission  Discharged 11/2/2021 - 11/4/2021 (2 days)   Last attending ? Treatment team Acute hypoxemic respiratory failure due to COVID-19 (CMS/HCC) Hospital Problems           POA  Hypertension Yes    Diabetes mellitus (CMS/HCC) Yes        Paroxysmal atrial fibrillation (CMS/HCC) Yes    Pneumonia due to COVID-19 virus Yes      HPI: The patient is an 78 y.o. female.    There is no known COVID-19 infection diagnosed last week.  Her husband was in the hospital last week with COVID-19.  She received monoclonal antibody infusion on Friday.  She is fully vaccinated.  However last 24 hours she started running fevers, she started feeling more ill, she started to feel like her heart was racing and she knows she has atrial fibrillation.  Came emergency room for evaluation.  Emergency room was noted to be hypoxic 87% on room air.  She was sinus tachycardia consistent with her lung disease.  Chest x-ray consistent with Covid pneumonia.  She was referred for inpatient management of her Covid infection.   Hospital Course:   78-year-old female with history of A. fib diabetes mellitus hypertension presented with shortness of H&P done admitting hospitalist for details.  Patient was a COVID-19 vaccinated was diagnosed having Covid recently, received multiple antibiotics outpatient basis came with worsening shortness of breath patient was also hypoxic requiring oxygen, patient received dexamethasone and remdesivir, shortness of breath gradually improved oxygen patient normalized, patient on room air since yesterday.  Patient was discharged on p.o. dexamethasone for five more days.  ED  Discharged 11/13/2021 (3 hours)  Treatment team Palpitations  History of COVID-19   Anticoagulated   Atrial fibrillation with RVR (CMS/HCC)    The patient is a 78 y.o. female presenting to the ED with chief complaint of increased heart rate and palpitations, patient recently in the hospital couple weeks ago for Covid pneumonia, has been doing well, over the past week has been having some abdominal discomfort with nausea.  Today she had increased heart rate and palpitations.  Has a history of atrial fibrillation is on Eliquis.  Denies any chest pain or shortness of breath.   Prehospital EKG 120 atrial fibrillation   Patient right now feels back to baseline, heart rate on arrival 50-60 No complaints of chest pain or abdominal pain, no recent other illness, symptoms moderate, nothing else makes it better or worse, no other relieving or mitigating factors
930AM pt recvd shot 12:00 sore throat-sl swollen tongue; 1:00 chills, achy feeling-4:00 left work; slept all evening & next day-following day blaw but OK- returned to work Monday;
pt recv vax 20MAR98 & has been covered in hives since;placed on med 31MAR98 then returned to hosp , 31MAR still itchy w/erythematous rash;
Injection site pain for 3 days, headaches for 3 days, muscle pain starting 2 days after and ongoing, same arm armpit swelling and pain in lymph nodes 2 days after and ongoing
pt recvd vax;area of induration/erythema (approx 3x5cm) on lt arm around inject site on 19dec94; starting approx 24-48 hrs p/ inject;
No additional adverse events; expired doses of PROQUAD were administered to 3 different patients; This spontaneous report was received from a registered nurse referring to a 4-year-old male patient. No information about the patient's pertinent medical history and drug reactions or allergies was provided. Concurrent conditions included chronic otitis media, and concomitant vaccines included diphtheria vaccine toxoid (+) pertussis vaccine acellular 3-component (+) polio vaccine inact 3v (vero) (+) tetanus vaccine toxoid (KINRIX).   On 18-APR-2022 at 09:08, the patient was vaccinated with an expired dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) subcutaneously in his left arm for prophylaxis (dose, vaccine scheme and lot number were not reported; expiration date 14-APR-2022) (expired product administered).  Product had never experienced temperature excursion and had supported outcome.   No adverse event reported.; Sender's Comments:  US-009507513-2204USA007779:
Rheumatoid arthritis flare up; This is a solicited report received from contactable reporter(s) (Consumer or other non HCP) for a sponsored program. The reporter is the patient. Other Case identifier(s): 22K-163-4277215-00.  A 37 year-old female patient received bnt162b2 (BNT162B2), intramuscular, administration date 08Dec2021 (Batch/Lot number: unknown) at the age of 37 years as dose 1, single and intramuscular, administration date 29Dec2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation; upadacitinib (RINVOQ), oral (ongoing) (Batch/Lot number: unknown) for rheumatoid arthritis. Relevant medical history included: "Rheumatoid arthritis" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: RHEUMATOID ARTHRITIS (medically significant), outcome "not recovered", described as "Rheumatoid arthritis flare up". The action taken for upadacitinib was dosage not changed.  The reporter's assessment of the causal relationship of the event Rheumatoid arthritis flare up (Rheumatoid arthritis) with the suspect product Rinvoq (Upadacitinib) was provided as Reasonable possibility. The reporter's assessment of the causal relationship of the event Rheumatoid arthritis flare up (Rheumatoid arthritis) with the suspect product BNT162B2 (Pfizer Biontech COVID-19 Vaccine) was provided as Possible. Since no determination has been received, the case is managed based on the company causality assessment.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on temporal association, there is reasonable possibility of causal association between the Reported events and the suspect drug BNT162B2.  The impact of this report on the benefit/risk profile of the Pfizer drug is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Headache, Myalgia, Arthralgia, Fever,  fatigue Narrative:
Your child received a vaccination at our clinic during the period between February 28 and April 16, 2020. During the period between February 28th, 2020 and March 2nd, 2020, our data logger had a technical malfunction that we were not aware of and it stopped sending its temperature recordings to the system.  During that period the fridge never stopped working. The temperature logs of the fridge before and after the incident were always within required range. Our fridge has been always in a perfect new condition and never had any temperature problems previously. There was no power outage in the area or inside the office during that period as well.       The CDC requires continuous temperature monitoring of all VFC vaccines and due to lack of continuous temperature data documentation, the vaccine manufacturers have determined that the doses administered on these dates should be re-administered to ensure proper effectiveness.